Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 3/20 | 0.47 |
| ▸ | BMP1 | P13497 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | FPR2 | P25090 | 4/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111552 | 0.93 | MEN1 (0.56) | MEN1KMT2AMAPTMCHR1FPR2 | |
| SCHEMBL4106222 | 0.89 | MEN1 (0.52) | MEN1KMT2ACCR3MAPTMCHR1 | |
| SCHEMBL4119675 | 0.89 | MEN1 (0.52) | MEN1KMT2ACCR3BMP1MCHR1 | |
| SCHEMBL4119984 | 0.88 | MEN1 (0.51) | MEN1KMT2AMCHR1FPR2CNR1 | |
| SCHEMBL4112236 | 0.88 | CNR1 (0.56) | MEN1KMT2AMAPTMCHR1CNR1 | |
| SCHEMBL4107568 | 0.87 | MCHR1 (0.58) | MEN1KMT2ACCR3BMP1MCHR1 | |
| SCHEMBL4113690 | 0.85 | MEN1 (0.50) | MEN1KMT2ACCR3BMP1MCHR1 | |
| SCHEMBL4125813 | 0.82 | GHSR (0.46) | MEN1KMT2AMAPTMCHR1GHSR | |
| SCHEMBL4125793 | 0.82 | EPHX2 (0.53) | CCR3MAPT | |
| SCHEMBL4116393 | 0.81 | EPHX2 (0.52) | CCR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | MEN1 4167/4885KMT2A 2720/4885CCR3 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.